Aliev T, Yudkin D
Front Med (Lausanne). 2025; 11:1499605.
PMID: 40007819
PMC: 11859266.
DOI: 10.3389/fmed.2024.1499605.
Presa M, Bailey R, Ray S, Bailey L, Tata S, Murphy T
Commun Med (Lond). 2025; 5(1):29.
PMID: 39870870
PMC: 11772666.
DOI: 10.1038/s43856-025-00734-9.
Guibinga G, Do J, Chu B, Gu Y, Kikkawa R, Li X
Mol Ther Methods Clin Dev. 2024; 32(4):101371.
PMID: 39717225
PMC: 11664412.
DOI: 10.1016/j.omtm.2024.101371.
Xu L, Yao S, Ding Y, Xie M, Feng D, Sha P
J Transl Med. 2024; 22(1):866.
PMID: 39334366
PMC: 11429861.
DOI: 10.1186/s12967-024-05661-2.
Slyk Z, Stachowiak N, Malecki M
Biomedicines. 2024; 12(7).
PMID: 39062095
PMC: 11274884.
DOI: 10.3390/biomedicines12071523.
Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1/2 trial interim results.
Sevigny J, Uspenskaya O, Heckman L, Wong L, Hatch D, Tewari A
Nat Med. 2024; 30(5):1406-1415.
PMID: 38745011
PMC: 11108785.
DOI: 10.1038/s41591-024-02973-0.
Pre-clinical delivery of gene therapy products to the cerebrospinal fluid: challenges and considerations for clinical translation.
Salegio E, Hancock K, Korszen S
Front Mol Neurosci. 2023; 16:1248271.
PMID: 37664241
PMC: 10469667.
DOI: 10.3389/fnmol.2023.1248271.
Intrathecal AAV9/AP4M1 gene therapy for hereditary spastic paraplegia 50 shows safety and efficacy in preclinical studies.
Chen X, Dong T, Hu Y, De Pace R, Mattera R, Eberhardt K
J Clin Invest. 2023; 133(10).
PMID: 36951961
PMC: 10178841.
DOI: 10.1172/JCI164575.
Subpial delivery of adeno-associated virus 9-synapsin-caveolin-1 () preserves motor neuron and neuromuscular junction morphology, motor function, delays disease onset, and extends survival in hSOD1 mice.
Wang S, Ichinomiya T, Savchenko P, Wang D, Sawada A, Li X
Theranostics. 2022; 12(12):5389-5403.
PMID: 35910808
PMC: 9330519.
DOI: 10.7150/thno.72614.
Assessment of AAV9 distribution and transduction in rats after administration through Intrastriatal, Intracisterna magna and Lumbar Intrathecal routes.
Chandran J, Chowdhury E, Perkinton M, Jamier T, Sutton D, Wu S
Gene Ther. 2022; 30(1-2):132-141.
PMID: 35637286
DOI: 10.1038/s41434-022-00346-1.
AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System.
Marino M, Holt M
Front Neurol. 2022; 13:870799.
PMID: 35493843
PMC: 9039256.
DOI: 10.3389/fneur.2022.870799.
Mosaic dysfunction of mitophagy in mitochondrial muscle disease.
Mito T, Vincent A, Faitg J, Taylor R, Khan N, McWilliams T
Cell Metab. 2022; 34(2):197-208.e5.
PMID: 35030325
PMC: 8815775.
DOI: 10.1016/j.cmet.2021.12.017.
AAV9/MFSD8 gene therapy is effective in preclinical models of neuronal ceroid lipofuscinosis type 7 disease.
Chen X, Dong T, Hu Y, Shaffo F, Belur N, Mazzulli J
J Clin Invest. 2022; 132(5).
PMID: 35025759
PMC: 8884910.
DOI: 10.1172/JCI146286.
Pilot Study Assessing the Impact of Intrathecal Administration of Variants AAV-PHP.B and AAV-PHP.eB on Brain Transduction in Adult Rhesus Macaques.
Arotcarena M, Dovero S, Biendon N, Dutheil N, Planche V, Bezard E
Front Bioeng Biotechnol. 2021; 9:762209.
PMID: 34869273
PMC: 8634843.
DOI: 10.3389/fbioe.2021.762209.
Adeno-associated viral vector serotype 9-based gene replacement therapy for -related Leigh syndrome.
Ling Q, Rioux M, Hu Y, Lee M, Gray S
Mol Ther Methods Clin Dev. 2021; 23:158-168.
PMID: 34703839
PMC: 8517205.
DOI: 10.1016/j.omtm.2021.09.001.
High throughput screening of novel AAV capsids identifies variants for transduction of adult NSCs within the subventricular zone.
Kremer L, Cerrizuela S, Dehler S, Stiehl T, Weinmann J, Abendroth H
Mol Ther Methods Clin Dev. 2021; 23:33-50.
PMID: 34553001
PMC: 8427210.
DOI: 10.1016/j.omtm.2021.07.001.
Investigating Immune Responses to the scAAV9- Gene Therapy Treatment in Tay-Sachs Disease and Sandhoff Disease Mouse Models.
Kot S, Karumuthil-Melethil S, Woodley E, Zaric V, Thompson P, Chen Z
Int J Mol Sci. 2021; 22(13).
PMID: 34201771
PMC: 8268035.
DOI: 10.3390/ijms22136751.
Gene Therapy for Lysosomal Storage Disorders: Ongoing Studies and Clinical Development.
Massaro G, Geard A, Liu W, Coombe-Tennant O, Waddington S, Baruteau J
Biomolecules. 2021; 11(4).
PMID: 33924076
PMC: 8074255.
DOI: 10.3390/biom11040611.
Pre-clinical Gene Therapy with AAV9/AGA in Aspartylglucosaminuria Mice Provides Evidence for Clinical Translation.
Chen X, Snanoudj-Verber S, Pollard L, Hu Y, Cathey S, Tikkanen R
Mol Ther. 2020; 29(3):989-1000.
PMID: 33186692
PMC: 7934581.
DOI: 10.1016/j.ymthe.2020.11.012.
Gene therapy for neurodegenerative disorders: advances, insights and prospects.
Chen W, Hu Y, Ju D
Acta Pharm Sin B. 2020; 10(8):1347-1359.
PMID: 32963936
PMC: 7488363.
DOI: 10.1016/j.apsb.2020.01.015.